Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies based on its proprietary technology, oligoDOM®, which is designed to induce powerful CD8 T-cell responses. Osivax' mission is to revolutionize influenza prevention with a universal flu vaccine covering both current and future influenza infections by leveraging its unique oligoDOM® technology platform.
Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies based on its proprietary technology, oligoDOM®, which is designed to induce powerful CD8 T-cell responses. Osivax' mission is to revolutionize influenza prevention with a universal flu vaccine covering both current and future influenza infections by leveraging its unique oligoDOM® technology platform.
Osivax was created as a spin-off of Imaxio, a commercial-stage vaccine company, to accelerate the development of the oligoDOM® technology platform, which capitalizes on:
Osivax's lead program is a game-changing universal influenza vaccine
Osivax relies on an international leadership team with complementary life science experiences and a prestigious international Scientific and Clinical Advisory Board with industry and academic expertise
Osivax is based in Lyon (France) and Liège (Belgium), two leading clusters of vaccine R&D in Europe.
Osivax remains open to new collaborations, with partners looking for technologies to improve the immune response on otherwise poorly immunogenic antigens
(1) Hayward AC, Wang L, Goonetilleke N, et al. Natural T Cell–mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study. American Journal of Respiratory and Critical Care Medicine. 2015;191(12):1422-1431. doi:10.1164/rccm.201411-1988OC.
- Over 12 years of R&D on a breakthrough approach to induce CD8 T-cell immunity
- A solid preclinical package developed by OSIVAX for its influenza vaccine candidate
- Clinical and preclinical data generated by leading independent teams in Europe (Oxford University, DKFZ / Heidelberg University, Inserm / CNRS...)
Osivax's lead program is a game-changing universal influenza vaccine
- Leveraging oligoDOM® technology, Osivax’s team is developing a recombinant vaccine candidate to prevent moderate to severe cases of seasonal and pandemic influenza
- The most advanced flu vaccine candidate is in Phase 1 clinical development. Osivax is focused on providing proof-of-concept in Influenza firstly to save lives and secondly to apply the platform to other infectious and immune system-associated diseases
- This oligoDOM®-based influenza vaccine induces powerful CD8 T-cell immune responses against the highly conserved flu NucleoProtein (NP) and won’t require annual updates as NP is a highly conserved antigen
- The aim is to develop a universal influenza vaccine providing greater than 70% protection from morbidity and mortality caused by current and future A- and B-strain influenza viruses (1)
- Osivax vaccine program is currently in phase I clinical trial, actively preparing a phase IIa
Osivax relies on an international leadership team with complementary life science experiences and a prestigious international Scientific and Clinical Advisory Board with industry and academic expertise
Osivax is based in Lyon (France) and Liège (Belgium), two leading clusters of vaccine R&D in Europe.
Osivax remains open to new collaborations, with partners looking for technologies to improve the immune response on otherwise poorly immunogenic antigens
(1) Hayward AC, Wang L, Goonetilleke N, et al. Natural T Cell–mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study. American Journal of Respiratory and Critical Care Medicine. 2015;191(12):1422-1431. doi:10.1164/rccm.201411-1988OC.